<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286399</url>
  </required_header>
  <id_info>
    <org_study_id>ADOPT169609</org_study_id>
    <nct_id>NCT04286399</nct_id>
  </id_info>
  <brief_title>Asian Diabetes Outcomes Prevention Trial</brief_title>
  <acronym>ADOPT</acronym>
  <official_title>Asian Diabetes Outcomes Prevention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Centre Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medanta, The Medicity, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Foundation of India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Putrajaya Hospital, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiti Teknologi Mara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart Centre Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify patients with DM at high risk of CVD using elevated&#xD;
      N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (&gt;125pg/mL), and (2) intensify&#xD;
      therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose&#xD;
      co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this&#xD;
      high-risk DM population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Cardiovascular events are the leading cause of death among patients with diabetes. Early&#xD;
      identification of high-risk diabetic (DM) patients for intensification of preventive therapy&#xD;
      may prevent cardiovascular events.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      Among biomarker (N-terminal pro-B-type natriuretic peptide, NT-proBNP)-identified high-risk&#xD;
      type 2 DM patients without pre-existing cardiovascular disease, to test if intensive&#xD;
      preventive therapy (high dose renin-angiotensin-aldosterone system inhibitors [RAASi],&#xD;
      beta-blockade, sodium-glucose co-transporter 2 inhibitors [SGLT2i]) may be associated with&#xD;
      reduced cardiovascular events compared to standard of care.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Prospective multinational randomized open-label, parallel group, active-controlled, two-arm,&#xD;
      long-term morbidity and mortality trial involving 5 Asian regions (Singapore, Malaysia,&#xD;
      China, Taiwan, India; estimated 6 sites each) with patients followed for 2 years.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Adults with type 2 DM without known cardiovascular disease (defined as known coronary&#xD;
      stenosis &gt; 70%, reduced left ventricular ejection fraction &lt; 40%, or a history of myocardial&#xD;
      infarction/coronary revascularization/heart failure hospitalization/stroke/prior&#xD;
      non-traumatic lower limb amputation or angioplasty) and with NT-proBNP &gt; 125 pg/mL&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      The goal is to include approximately 2,400 patients. It is estimated that about 3,000&#xD;
      patients with NT-proBNP &gt; 125pg/mL have to be screened. The screen failure rate, for reasons&#xD;
      other than NT-proBNP, is anticipated to be approximately 20%. The observation period is&#xD;
      planned to last for two years. However, the trial is event driven and will continue until&#xD;
      predefined event rate is reached (see sample size calculation). The total trial duration is&#xD;
      expected to last for four years (two years of recruitment and a two-year observation period&#xD;
      after last patient in). Every patient will remain in the study for two years after&#xD;
      randomization.&#xD;
&#xD;
      Visits:&#xD;
&#xD;
      Visit 1:&#xD;
&#xD;
      Pre- Screening&#xD;
&#xD;
      Patients who fulfil the first three pre-screening criteria will proceed for NT-proBNP&#xD;
      Point-of-Care (POC) testing:&#xD;
&#xD;
        -  Type 2 diabetes for at least 6 months (ADA definition)&#xD;
&#xD;
        -  Informed consent&#xD;
&#xD;
        -  Check Inclusion/exclusion criteria&#xD;
&#xD;
        -  NT-proBNP (assessed through local point of care device) *If the results for NT-proBNP&#xD;
           fall &gt; 125pg/mL, the patients will proceed for Full-Screening.&#xD;
&#xD;
      Full- Screening&#xD;
&#xD;
        -  Patient enrolment details&#xD;
&#xD;
        -  Demographic data&#xD;
&#xD;
        -  Patient diary (blood pressure, heart rate, blood glucose) - distribution (optional)&#xD;
&#xD;
        -  Vital signs -pulse rate and blood pressure&#xD;
&#xD;
        -  Height, weight, waist and hip circumference&#xD;
&#xD;
        -  Medical history (DM, cardiovascular, general and behavioural)&#xD;
&#xD;
        -  Routine Blood sampling for local laboratory, collected from medical record, if available&#xD;
&#xD;
        -  Blood collection for Biomarker analysis (Refer to Section 5.3 and Biospecimen manual)&#xD;
&#xD;
        -  Urine sample for Urine Albumin/creatinine ratio, collected from medical record, if&#xD;
           available&#xD;
&#xD;
        -  Electronic randomization (Section 2.6)&#xD;
&#xD;
        -  12-Lead Electrocardiogram (ECG), collected from medical record, if available (For&#xD;
           Singapore sites, ECG values are to be acquired, if not available from medical record)&#xD;
&#xD;
        -  EuroQoL questionnaire (EQ-5D-5L)&#xD;
&#xD;
        -  Drug prescription assessment&#xD;
&#xD;
        -  Health service resource utilisation assessment&#xD;
&#xD;
        -  Cardiovascular events assessment&#xD;
&#xD;
        -  Baseline Adverse Events assessment&#xD;
&#xD;
        -  Echocardiography measurements, collected from medical records, if available (all sites)&#xD;
&#xD;
        -  Echocardiography image acquisition (for Singapore and Taiwan sites only - optional)&#xD;
&#xD;
      Interim visits for the treatment group Visit 1-4 is mandatory for all patients, interim&#xD;
      visits (between Visits 1-2) only for the intensive treatment group for up-titration of RAASi&#xD;
      and beta-blockers and initiation/continuation of SGLT2i. The frequency is up to the treating&#xD;
      physician and titration steps. A visit is not mandatory for each titration step.&#xD;
&#xD;
        -  Patient diary - collect for assessment and distribute new (optional)&#xD;
&#xD;
        -  Vital signs -pulse rate and blood pressure&#xD;
&#xD;
        -  Routine blood sampling for local laboratory, collected from medical record, if available&#xD;
&#xD;
        -  Drug prescription assessment for further up-titration&#xD;
&#xD;
        -  Health service resource utilisation assessment&#xD;
&#xD;
        -  Cardiovascular events assessment&#xD;
&#xD;
        -  Adverse Events assessment Note: SBP and heart rate should not permanently decrease below&#xD;
           100mmHg and 60bpm respectively.&#xD;
&#xD;
      Visit 2 (3 months ± 1 week)&#xD;
&#xD;
        -  Patient diary - collect for assessment and distribute new (optional)&#xD;
&#xD;
        -  Vital signs -pulse rate and blood pressure&#xD;
&#xD;
        -  Routine Blood sampling for local laboratory, collected from medical record, if available&#xD;
&#xD;
        -  Urine sample for Urine Albumin/creatinine ratio, collected from medical record, if&#xD;
           available&#xD;
&#xD;
        -  12-Lead Electrocardiogram (ECG), collected from medical record, if available (For&#xD;
           Singapore sites, ECG values are to be acquired, if not available from medical record)&#xD;
&#xD;
        -  Drug prescription assessment1&#xD;
&#xD;
        -  Health service resource utilisation assessment&#xD;
&#xD;
        -  Cardiovascular events assessment&#xD;
&#xD;
        -  Adverse Events assessment&#xD;
&#xD;
      Visit 3 (12 months ± 2 weeks)&#xD;
&#xD;
        -  Patient diary - collect for assessment and distribute new (optional)&#xD;
&#xD;
        -  NT-proBNP (assessed through local point of care device)&#xD;
&#xD;
        -  Vital signs -pulse rate and blood pressure&#xD;
&#xD;
        -  Height, weight, waist and hip circumference&#xD;
&#xD;
        -  Routine Blood sampling for local laboratory, collected from medical record, if available&#xD;
&#xD;
        -  Blood collection for Biomarker analysis (Refer to Section 5.3 and Biospecimen manual)&#xD;
&#xD;
        -  Urine sample for Urine Albumin/creatinine ratio, collected from medical record, if&#xD;
           available&#xD;
&#xD;
        -  12-Lead Electrocardiogram (ECG), collected from medical record, if available (For&#xD;
           Singapore sites, ECG values are to be acquired, if not available from medical record)&#xD;
&#xD;
        -  EuroQoL questionnaire (EQ-5D-5L)&#xD;
&#xD;
        -  Drug prescription assessment1&#xD;
&#xD;
        -  Health service resource utilisation assessment&#xD;
&#xD;
        -  Cardiovascular events assessment&#xD;
&#xD;
        -  Adverse Events assessment&#xD;
&#xD;
        -  Echocardiography image acquisition (for Taiwan only - optional)&#xD;
&#xD;
      Visit 4: End of Study (24 months ± 2 weeks)&#xD;
&#xD;
        -  Patient diary - collect for assessment and distribute new (optional)&#xD;
&#xD;
        -  Vital signs -pulse rate and blood pressure&#xD;
&#xD;
        -  Height, weight, waist and hip circumference&#xD;
&#xD;
        -  Routine Blood sampling for local laboratory, collected from medical record, if available&#xD;
&#xD;
        -  Urine sample for Urine Albumin/creatinine ratio, collected from medical record, if&#xD;
           available&#xD;
&#xD;
        -  12-Lead Electrocardiogram (ECG), collected from medical record, if available (For&#xD;
           Singapore sites, ECG values are to be acquired, if not available from medical record)&#xD;
&#xD;
        -  EuroQoL questionnaire (EQ-5D-5L)&#xD;
&#xD;
        -  Drug prescription assessment&#xD;
&#xD;
        -  Health service resource utilisation assessment&#xD;
&#xD;
        -  Cardiovascular events assessment&#xD;
&#xD;
        -  Adverse Events assessment&#xD;
&#xD;
      Long-term follow-up (LTFU) (36 and 48 months ± 3 weeks)&#xD;
&#xD;
        -  Follow up through telephone contact or population registry (if access allowed) until&#xD;
           completion of the study&#xD;
&#xD;
        -  Long-term cardiovascular events, mortality and hospitalizations.&#xD;
&#xD;
        -  Adverse Events assessment&#xD;
&#xD;
        -  For all patients, irrespective of whether they reach these two LTFU time points, a final&#xD;
           follow-up should be performed at the end of study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2034</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint based on the first occurrence of cardiovascular death or major adverse cardiovascular event</measure>
    <time_frame>48 months</time_frame>
    <description>Stroke/myocardial infarction/heart failures events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intensive Treatment Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High dose of RAASi and beta-blockers (unless contraindicated) as well as preferential use of SGLT2i as per local drug label guidelines on top of standard therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy where the use of SGLT2i at randomization is not encouraged but RAASi and beta-blockers (except for maximal dosage) are allowed. Prescription or up-titration of the study drugs listed under Intensive Treatment is not encouraged. If investigators/treating physicians feel that further prescription or up-titration is required, a thorough justification is mandatory. Unless there is clinically irrefutable reason, every attempt should be made to use other blood pressure lowering drugs than RAASi or beta-blockers, as well as glucose lowering drugs than SGLT2i, in the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin-angiotensin-aldosterone system inhibitors</intervention_name>
    <description>Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.</description>
    <arm_group_label>Intensive Treatment Group</arm_group_label>
    <other_name>Angiotensin-converting enzyme (ACE) inhibitors</other_name>
    <other_name>Angiotensin II receptor blockers (ARBs)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker</intervention_name>
    <description>Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.</description>
    <arm_group_label>Intensive Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product</intervention_name>
    <description>Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.</description>
    <arm_group_label>Intensive Treatment Group</arm_group_label>
    <other_name>SGLT2 inhibitors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes for at least six months&#xD;
&#xD;
          -  ≥ 40 years of age, men or women&#xD;
&#xD;
          -  No known cardiovascular disease ( defined as known coronary stenosis &gt; 70%, reduced&#xD;
             left ventricular ejection fraction &lt; 40%, or a history of myocardial infarction/&#xD;
             coronary revascularization/ heart failure hospitalization/ stroke/ prior non-traumatic&#xD;
             lower limb amputation or angioplasty)&#xD;
&#xD;
          -  NT-proBNP &gt; 125 pg/mL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to any of the drugs investigated as well as known or&#xD;
             suspected contraindications to the study drugs or previous history of intolerance&#xD;
&#xD;
          -  Patients already on a maximum dose of RAASi or beta-blocker&#xD;
&#xD;
          -  History of DM ketoacidosis/Type 1 DM&#xD;
&#xD;
          -  eGFR &lt; 45ml/min/1.73m2&#xD;
&#xD;
          -  Symptomatic hypotension and/or Visit 1 systolic blood pressure (SBP) &lt; 100mmHg.&#xD;
&#xD;
          -  Symptomatic bradycardia, high-grade AV blocks (Grade 2 and 3) and/or Visit 1 heart&#xD;
             rate (HR) &lt; 60bpm.&#xD;
&#xD;
          -  Any disease other than diabetes lowering the patient's life expectancy to less than&#xD;
             two years.&#xD;
&#xD;
          -  Chronic infections (E.g. chronic cystitis, recurrent urinary tract infections) or&#xD;
             malignancies or uncontrolled thyroid disorder or liver disease&#xD;
&#xD;
          -  Systemic treatment with corticosteroids.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Any other clinical condition that might affect patients' safety during trial, at the&#xD;
             investigator's discretion.&#xD;
&#xD;
          -  Participation in an investigational drug trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Lam Prof</last_name>
    <role>Study Director</role>
    <affiliation>National Heart Centre Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serene Ng Miss</last_name>
    <phone>67042232</phone>
    <email>serene.ng.b.l@singhealth.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salma Asali Miss</last_name>
    <phone>67042303</phone>
    <email>asali.salma@singhealth.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Singapore General Hospital (SGH)</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serene Ng, Ms</last_name>
      <phone>(+65) 6704 2232</phone>
      <email>serene.ng.b.l@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

